REGISTRATION IS NOW OPEN!
Save up to $700 with the Super Early Bird Rate using Promo Code SUPER
Only 10 Passes Available. Offer Expires March 31st
The premiere event developed by, and dedicated to communicators in Life Sciences...
As an event developed by industry leaders, the Pharma PR & Communications Summit delivers the chance to hear from top organizations on conquering new strategies, demonstrating value to the press and public, and pushing boundaries with innovative approaches to outreach. On a personal level, we'll also provide key opportunities to learn from and expand upon your network to ensure you stay relevant at your current company or wherever your career may take you. This is a must-attend event for anyone working in the life science communications industry.
Top Reasons to Attend the Fierce Pharma PR & Communications Summit
An Event Tailored for You
Stay Ahead of Current Trends
Diverse Speaking Staff
Great Conference Program
Networking Opportunities
Who Should Attend?
Life science marketing professionals from pharmaceutical, biotechnology and medical device companies, as well as agencies responsible for:
-
Communications: Corporate, Brand, Internal, External, Integrated, Multichannel
-
Public /Media Relations
-
Investor Relations
-
Diversity, Equity and Inclusion
-
Employee Engagement
-
Social Media
-
Public/Government Affairs
-
Advocacy, and Patient Relations
-
Community/Advocacy Relations
-
Marketing
-
Public Policy
Maximize learning by attending as a group and save 25% or more.
If you plan to send multiple people from your team to the Fierce Pharma PR & Communications Summit, please contact us for custom group pricing.
Previous Attendees of the Fierce Pharma PR & Communications Summit Include Communications Executives from Top Pharmaceutical and Biotech Companies. Below is a Sample of Some of the Companies That Attended:
- AbbVie
- Acorda Therapeutics, Inc.
- Alkermes
- Allstate
- Alnylam Pharmaceuticals
- Amgen
- Arvinas, Inc.
- Astellas Pharma
- Asuragen
- Aztiq
- Bavarian Nordic
- BeiGene
- BI Worldwide
- Biogen
- BioNJ
- bluebird bio
- Boehringer Ingelheim
- Bristol Myers Squibb
- Caladrius Biosciences
- Clover Biopharmaceuticals
- Clyde Group
- CSL Behring
- Cullinan Oncology
- Deerfield Management
- Dicerna/Novo Nordisk
- Endo Pharmaceuticals
- Finn Partners
- Forge Biologics
- FTI Consulting
- Gagen MacDonald
- GCI Health
- Golin Health
- Grand River Aseptic Manufacturing
- GSK
- HDMZ
- Homology Medicines
- Horizon Therapeutics
- Insmed
- Ionis Pharmaceuticals
- Kaléo
- LifeSci Advisors LLC
- LifeSci Communications
- Ligand Pharmaceuticals
- Lyndra Therapeutics
- Marina Maher Communications
- MeiraGTx
- Merck
- Minaris Regenerative Medicine
- Mirati Therapeutics
- Nexus Pharmaceuticals
- Novo Nordisk
- Ocugen
- Organon
- Passage Bio
- Pfizer
- Phizzle
- Boston University College of Communication
- Quest Diagnostics
- Real Chemistry
- Red Havas
- Regeneron
- Roche Diagnostics
- Rutgers University
- RXMosaic
- Sage Therapeutics
- Spark Therapeutics
- Spectrum Science
- Sumitovant Biopharma
- Takeda
- TellMed Strategies
- Teva Pharmaceuticals
- The Female Quotient (TFQ)
- The Harris Poll
- twelvenote
- Venatorx Pharmaceuticals
- Vor Bio
- Weber Shandwick